(19) & (11) EP 2 474 632 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.07.2012 Bulletin 2012/28 C12Q 1/68 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 16/18 (2006.01) (2006.01) (21) Application number: 12163442.2 C07K 16/28 (22) Date of filing: 22.12.2003 (84) Designated Contracting States: • Devlin, James AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Alameda, CA 94502 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Cargill, Michele Alameda, CA 94502 (US) (30) Priority: 20.12.2002 US 434778 P 30.04.2003 US 466412 P (74) Representative: Jones Day 10.03.2003 US 453135 P Rechtsanwälte, Attorneys-at-Law 23.09.2003 US 504955 P Patentanwälte Intellectual Property (62) Document number(s) of the earlier application(s) in Prinzregentenstraße 11 accordance with Art. 76 EPC: 80538 München (DE) 03800092.3 / 1 583 771 Remarks: (71) Applicant: Celera Corporation •Thecomplete document including Reference Tables Alameda, CA 94502 (US) and the Sequence Listing can be downloaded from the EPO website (72) Inventors: •This application was filed on 05-04-2012 as a • Lakoubova, Olga divisional application to the application mentioned Alameda, CA 94502 (US) under INID code 62. (54) Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof (57) The present invention is based on the discovery of genetic polymorphisms that are associated with myo- cardial infarction. In particular, the present invention re- lates to nucleic acid molecules containing the polymor- phisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucle- ic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. EP 2 474 632 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 474 632 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention is in the field of myocardial infarction diagnosis and therapy. In particular, the present invention relates to specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with myocardial infarction (including recurrent myocardial infarction) and related pathologies. Based on differences in allele frequencies in the myocardial infarction patient population relative to normal individuals, the naturally-occurring SNPs disclosed herein can be used as targets for the design of diagnostic reagents and the development of therapeutic agents, 10 as well as for disease association and linkage analysis. In particular, the SNPs of the present invention are useful for identifying an individual who is at an increased or decreased risk of developing myocardial infarction and for early detection of the disease, for providing clinically important information for the prevention and/or treatment of myocardial infarction, and for screening and selecting therapeutic agents. The SNPs disclosed herein are also useful for human identification applications. Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and 15 their encoded products are provided. BACKGROUND OF THE INVENTION Myocardial Infarction (including Recurrent Myocardial Infarction) 20 [0002] Myocardial infarction (MI) is the most common cause of mortality in developed countries. It is a multifactorial disease that involves atherogenesis, thrombus formation and propagation. Thrombosis can result in complete or partial occlusion of coronary arteries. The luminal narrowing or blockage of coronary arteries reduces oxygen and nutrient supply to the cardiac muscle (cardiac ischemia), leading to myocardial necrosis and/or stunning. MI, unstable angina, 25 or sudden ischemic death are clinical manifestations of cardiac muscle damage. All three endpoints are part of the Acute Coronary Syndrome since the underlying mechanisms of acute complications of atherosclerosis are considered to be the same. [0003] Atherogenesis, the first step of pathogenesisof MI, is a complex interaction between blood elements, mechanical forces, disturbed blood flow, and vessel wall abnormality. On the cellular level, these include endothelial dysfunction, 30 monocytes/macrophages activation by modified lipoproteins, monocytes/ macrophages migration into the neointima and subsequent migration and proliferation of vascular smooth muscle cells (VSMC) from the media that results in plaque accumulation. [0004] In recent years, an unstable (vulnerable) plaque was recognized as an underlying cause of arterial thrombotic events and MI. A vulnerable plaque is a plaque, often not stenotic, that has a high likelihood of becoming disrupted or 35 eroded, thus forming a thrombogenic focus. Two vulnerable plaque morphologies have been described. A first type of vulnerable plaque morphology is a rupture of the protective fibrous cap. It can occur in plaques that have distinct morphological features such as large and soft lipid pool with distinct necrotic core and thinning of the fibrous cap in the region of the plaque shoulders. Fibrous caps have considerable metabolic activity. The imbalance between matrix synthesis and matrix degradation thought to be regulated by inflammatory mediators combined with VSMC apoptosis 40 are the key underlying mechanisms of plaque rupture. A second type of vulnerable plaque morphology, known as "plaque erosion", can also lead to a fatal coronary thrombotic event. Plaque erosion is morphologically different from plaque rupture. Eroded plaques do not have fractures in the plaque fibrous cap, only superficial erosion of the intima. The loss of endothelial cells can expose the thrombogenic subendothelial matrix that precipitates thrombus formation. This process could be regulated by inflammatory mediators. The propagation of the acute thrombi for both plaque rupture and plaque 45 erosion events depends on the balance between coagulation and thrombolysis. MI due to a vulnerable plaque is a complex phenomenon that includes: plaque vulnerability, blood vulnerability (hypercoagulation, hypothrombolysis), and heart vulnerability (sensitivity of the heart to ischemia or propensity for arrhythmia). [0005] Recurrent myocardial infarction can generally be viewed as a severe form of MI progression caused by multiple vulnerable plaques that are able to undergo pre- rupture or a pre- erosive state, coupled with extreme blood coagulability. 50 [0006] The incidence of MI is still high despite currently available preventive measures and therapeutic intervention. More than 1,500,000 people in the US suffer acute MI each year (many without seeking help due to unrecognized MI), and one third of these people die. The lifetime risk of coronary artery disease events at age 40 years is 42.4% for men (one in two) and 24.9% for women (one in four) (Lloyd-Jones DM; Lancet, 1999 353: 89-92). [0007] The current diagnosis of MI is based on the levels of troponin I or T that indicate the cardiac muscle progressive 55 necrosis, impaired electrocardiogram (ECG), and detection of abnormal ventricular wall motion or angiographic data (the presence of acute thrombi). However, due to the asymptomatic nature of 25% of acute MIs (absence of atypical chest pain, low ECG sensitivity), a significant portion of MIs are not diagnosed and therefore not treated appropriately (e.g., prevention of recurrent MIs). 2 EP 2 474 632 A2 [0008] Despite a very high prevalence and lifetime risk of MI, there are no good prognostic markers that can identify an individual with a high risk of vulnerable plaques and justify preventive treatments. MI risk assessment and prognosis is currently done using classic risk factors or the recently introduced Framingham Risk Index. Both of these assessments put a significant weight on LDL levels to justify preventive treatment. However, it is well established that half of all MIs 5 occur in individuals without overt hyperlipidemia. Hence, there is a need for additional risk factors for predicting predis- position to MI. [0009] Other emerging risk factors are inflammatory biomarkers such as C- reactive protein (CRP), ICAM- 1, SAA, TNF α, homocysteine, impaired fasting glucose, new lipid markers (ox LDL, Lp- a, MAD-LDL, etc.) and pro-thrombotic factors (fibrinogen, PAI-1). Despite showing some promise, these markers have significant limitations such as low specificity 10 and low positive predictive value, and the need for multiple reference intervals to be used for different groups of people (e.g., males-females, smokers-non smokers, hormone replacement therapy users, different age groups). These limita- tions diminish the utility of such markers as independent prognostic markers for MI screening. [0010] Genetics plays an important role in MI risk. Families with a positive family history of MI account for 14% of the general population, 72% of premature MIs, and 48% of all MIs (Williams R R, Am J Cardiology, 2001; 87: 129). In addition, 15 replicated linkage studies have revealed evidence of multiple regions of the genome that are associated with MI and relevant to MI genetic traits, including regions on chromosomes 14, 2, 3 and 7 (Broeckel U, Nature Genetics, 2002; 30: 210; Harrap S, Arterioscler Thromb Vasc Biol, 2002; 22: 874-878, Shearman A, Human Molecular Genetics, 2000, 9; 9,1315-1320), implying that genetic risk factors influence the onset, manifestation, and progression of MI. Recent as- sociation studies have identified allelic variants that are associated with acute complications of coronary heart disease, 20 including allelic variants of the ApoE, ApoA5,